指南与共识其他结缔组织病

幼年系统性硬化症12个月药物试验的拟定疗效参数:汉堡国际共识会议结果

Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings.
指南 / 共识 · Arthritis Care Res (Hoboken) · 2023-09-12

该共识通过4次面对面会议,由27名多学科成员(含患者)组成的团队,基于成人数据、有限的儿童文献及2个幼年系统性硬化症患者队列数据,采用名义群体技术投票,就开放标签12个月临床试验应评估的领域和条目达成共识。

要点

  • 共识推荐在幼年系统性硬化症开放标签12个月临床试验中评估全局疾病活动度、皮肤、雷诺现象、指端溃疡、肌肉骨骼、心脏、肺、肾、胃肠道受累及生活质量领域。
  • 14个疗效测量条目获得100%同意,1个条目获得91%同意,1个条目获得86%同意。
  • 生物标志物和生长/发育领域被移至研究议程。

核心结论

  • 共识就幼年系统性硬化症开放标签12个月临床试验应评估的多个领域和条目达成一致,并制定了未来发展的研究议程。

研究设计与样本

  • 本提案是4次面对面共识会议的结果,参与者为27名多学科团队成员,包括儿童风湿病学家、成人风湿病学家、皮肤科医生、儿童心脏病专家、肺科医生、胃肠病学家、一名统计学家和患者。
  • 过程中回顾了该领域现有成人数据、较有限的幼年系统性硬化症疗效儿童文献以及2个幼年系统性硬化症患者队列的数据,以协助做出有依据的数据驱动决策。
  • 使用名义群体技术对每个领域条目作为开放标签12个月幼年系统性硬化症临床试验疗效测量进行投票并达成一致。

主要发现

  • 投票后达成一致的领域为全局疾病活动度、皮肤、雷诺现象、指端溃疡、肌肉骨骼、心脏、肺、肾、胃肠道受累和生活质量。
  • 14个疗效测量条目获得100%同意,1个条目获得91%同意,1个条目获得86%同意。
  • 生物标志物和生长/发育领域被移至研究议程。

关键数值与推荐

  • 14个疗效测量条目获得100%同意。
  • 1个条目获得91%同意。
  • 1个条目获得86%同意。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Juvenile systemic sclerosis (SSc) is an orphan disease, associated with high morbidity and mortality. New treatment strategies are much needed, but clearly defining appropriate outcomes is necessary if successful therapies are to be developed. Our objective here was to propose such outcomes. METHODS: This proposal is the result of 4 face-to-face consensus meetings with a 27-member multidisciplinary team of pediatric rheumatologists, adult rheumatologists, dermatologists, pediatric cardiologists, pulmonologists, gastroenterologists, a statistician, and patients. Throughout the process, we reviewed the existing adult data in this field, the more limited pediatric literature for juvenile SSc outcomes, and data from 2 juvenile SSc patient cohorts to assist in making informed, data-driven decisions. The use of items for each domain as an outcome measure in an open label 12-month clinical trial of juvenile SSc was voted and agreed upon using a nominal group technique. RESULTS: After voting, the domains agreed on were global disease activity, skin, Raynaud's phenomenon, digital ulcers, musculoskeletal, cardiac, pulmonary, renal, and gastrointestinal involvement, and quality of life. Fourteen outcome measures had 100% agreement, 1 item had 91% agreement, and 1 item had 86% agreement. The domains of biomarkers and growth/development were moved to the research agenda. CONCLUSION: We reached consensus on multiple domains and items that should be assessed in an open label, 12-month clinical juvenile SSc trial as well as a research agenda for future development.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Foeldvari I, Torok KS, Anton J, et al. Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings. Arthritis Care Res (Hoboken). 2023. PMID: 37332054. doi:10.1002/acr.25171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。